Figure 3. Overexpression of IL-17D in progressor tumors recruits NK cells that are required for tumor rejection in WT mice and promote M1 macrophage infiltration.

(A) Percentage of (7AAD^-, CD45⁺, CD3^-, NK1.1⁺) NK cells, (7AAD^-, CD45⁺, CD11b⁺, Ly6G⁺, MHCII^lo) neutrophils, (7AAD^-, CD45⁺, CD11b⁺, Ly6C^hi) monocytes/macrophage precursors, (7AAD^-, CD45⁺, F4/80⁺, Ly6C^lo, MHCII^hi, CD206^lo ) M1 macrophages, (7AAD^-, CD45⁺, F4/80⁺, Ly6C^lo, MHCII^lo, CD206^hi) M2 macrophages, (7AAD^-, CD45⁺, CD3⁺, CD4⁺, CD8^-) CD4⁺ T-cell, and (7AAD^-, CD45⁺, CD3⁺, CD4^-, CD8⁺) CD8⁺ T-cell infiltrating immune cells in F244 ctrl or ex17D tumors on d7 and d14 post transplantation in WT mice. (“Other” indicates infiltrating Ly6C-MHCII-NK1.1^-CD3^-immune cells).

(B) Percent infiltrating NK cells of total viable (7AAD^-) cells from transduced regressor and progressor tumors on d7 post tumor transplant in WT mice.

(C) Tumor growth of IL-17D overexpressing (ex17D) progressor tumors transplanted into WT mice receiving either i.p. injections of anti-NK1.1/ctrl IgG, or pre-immunized with transplantation of IL-17D overexpressing (ex17D) tumor cell lines.

(D) Percentage of M1 macrophages of total viable cells on d14 post tumor transplant of progressor tumor cell lines into WT, RAG2^-/-, or RAG2^-/- × γc^-/- hosts.

Data from (A-D) are representative of two independent experiments. Samples were compared using an unpaired, two-tailed Student's t test with Welch's correction. Error bars are depicted as ±SEM. (**P < 0.01, ***P < 0.001, ****P < 0.0001; NS, not significant). See also Figure S3.